Literature DB >> 10631653

How to improve the diagnostic process.

A Eisen1.   

Abstract

The existing therapeutic options for treating amyotrophic lateral sclerosis (ALS) are relatively limited but, as therapies improve, there will be a need for early diagnosis of this rare but fatal neurogenerative disorder. Early diagnosis not only requires the utility of a good biological marker, it also requires medical personnel who are experienced to consider/establish a diagnosis of ALS. In many countries, diagnosis of ALS follows a three-step process involving the family physician/practitioners, a community neurologist and an ALS specialist. This process is cumbersome and as the number of cases seen by the first two doctors is extremely small, their awareness is consequently low. There is an urgent need to improve the awareness of ALS in the family physicians but also within the general population. A number of elements which probably contribute to delays in achieving an early diagnosis of ALS will be discussed in this paper with the view of identifying how the diagnostic process can be improved.

Entities:  

Mesh:

Year:  1999        PMID: 10631653     DOI: 10.1007/bf03161082

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  19 in total

Review 1.  Clinical epidemiology of amyotrophic lateral sclerosis.

Authors:  B R Brooks
Journal:  Neurol Clin       Date:  1996-05       Impact factor: 3.806

Review 2.  Regulation of apoptosis resistance and ontogeny of age-dependent diseases.

Authors:  E Wang
Journal:  Exp Gerontol       Date:  1997 Jul-Oct       Impact factor: 4.032

3.  Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study.

Authors:  S Abrahams; L H Goldstein; J J Kew; D J Brooks; C M Lloyd; C D Frith; P N Leigh
Journal:  Brain       Date:  1996-12       Impact factor: 13.501

4.  Familial aggregation of amyotrophic lateral sclerosis, dementia, and Parkinson's disease: evidence of shared genetic susceptibility.

Authors:  D Majoor-Krakauer; R Ottman; W G Johnson; L P Rowland
Journal:  Neurology       Date:  1994-10       Impact factor: 9.910

5.  Prevention of motoneuron death by adenovirus-mediated neurotrophic factors.

Authors:  M Giménez y Ribotta; F Revah; L Pradier; I Loquet; J Mallet; A Privat
Journal:  J Neurosci Res       Date:  1997-05-01       Impact factor: 4.164

6.  Changing anesthesiologists' practice patterns. Can it be done?

Authors:  M M Cohen; D K Rose; D A Yee
Journal:  Anesthesiology       Date:  1996-08       Impact factor: 7.892

7.  Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF.

Authors:  P Aebischer; N A Pochon; B Heyd; N Deglon; J M Joseph; A D Zurn; E E Baetge; J P Hammang; M Goddard; M Lysaght; F Kaplan; A C Kato; M Schluep; L Hirt; F Regli; F Porchet; N De Tribolet
Journal:  Hum Gene Ther       Date:  1996-05-01       Impact factor: 5.695

Review 8.  Superoxide dismutase and neurofilament transgenic models of amyotrophic lateral sclerosis.

Authors:  B M Morrison; J H Morrison; J W Gordon
Journal:  J Exp Zool       Date:  1998 Sep-Oct 1

9.  Amyotrophic lateral sclerosis/parkinsonism/dementia: clinico-pathological correlations relevant to Guamanian ALS/PD.

Authors:  A J Hudson
Journal:  Can J Neurol Sci       Date:  1991-08       Impact factor: 2.104

Review 10.  Determinants of neuronal vulnerability in neurodegenerative diseases.

Authors:  B M Morrison; P R Hof; J H Morrison
Journal:  Ann Neurol       Date:  1998-09       Impact factor: 10.422

View more
  2 in total

Review 1.  Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature.

Authors:  Gary Ginsberg; Serena Lowe
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010-2015.

Authors:  Jaime Raymond; BjÖrn Oskarsson; Paul Mehta; Kevin Horton
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2019-05-26       Impact factor: 4.092

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.